BIT significantly cheaper than 2018-19 and de-risked.BIT has...

BIT significantly cheaper than 2018-19 and de-risked.
BIT has advisors on tap geared towards commercialisation.
The shift to the E protein for COVID/HIV - BIT has been on the money all along
The likelihood now of FDA emergency use approval. Far more likely than on HIV alone.
The timing of this new variant - if Delta was a massive headache, this new one is a tumor. Our technology's time has come....if big pharma cares little for a cure to HIV, I doubt they will resist an alternative remedy to covid that is available now.

Finally, only a few of us know what the time is....the rest of the market is still asleep on this (or has discredited BIT for not meeting 'their' timelines).

Note that accumulation has been steady and disciplined. Trader or smart money? DYOR.